Skip to main content
Explore URMC
menu

Yuhchyau Chen, M.D., Ph.D.

Contact Information

Phone Numbers

Appointment: (585) 275-2171

Fax: (585) 275-1531

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Radiation Oncology

Credentials

Specialties

  • Radiation Oncology - American Board of Radiology

Education

1990
MD | University of Washington School of Medicine

Post-doctoral Training & Residency

07/01/1992 - 07/01/1995
Fellowship in Clinical Fellow at Harvard Medical School

07/01/1991 - 07/01/1995
Residency in Radiation Oncology at Massachusetts General Hospital

07/01/1990 - 06/30/1992
Internship in Transitional at Virginia Mason Medical Center

VIEW ALL expand_more

Awards

2013 - Present
Richard T. Bell Endowed Professorship in Radiation Oncology
Sponsor: Department of Radiation Oncology
Location: University of Rochester

2013 - 2014
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

2012 - 2013
Philip Rubin Professorship in Radiation Oncology
Sponsor: Department of Radiation Oncology
Location: University of Rochester

2012 - 2013
Fellow
Sponsor: Hedwig van Ameringen Executive Leadership in Academic Medicine
Location: Drexel University College of Medicine

2011 - 2012
Patient and Family Centered Care Award
Sponsor: University of Rochester

2001 - 2002
Educator of the Year
Sponsor: The Association of Residents in Radiation Oncology

1997 - 1998
Buswell Fellowship Award
Sponsor: Department of Medicine
Location: University of Rochester

1995 - 1996
George Casarett Research Excellence Award
Sponsor: Department of Radiation Oncology
Location: University of Rochester

1993 - 1994
Clinical Oncology Fellowship
Sponsor: American Cancer Society

1986 - 1990
Course Honors
Sponsor: University of Washington School of Medicine

1983 - 1984
Graduate School Research Assistantship
Location: University of Washington School of Medicine

1982 - 1983
Research Assistantship in Surgery
Sponsor: University of Washington School of Medicine

VIEW ALL expand_more

Clinical Trials

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Lead Researcher: Yuhchyau Chen

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

View Study Details

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Lead Researcher: Yuhchyau Chen

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this trial is to find out if the addition of pembrolizumab to usual chemotherapy is better or worse than usual chemotherapy alone for non-small cell lung cancer.

View Study Details

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Lead Researcher: Yuhchyau Chen

This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.

View Study Details

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Lead Researcher: Yuhchyau Chen

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

View Study Details

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Lead Researcher: Yuhchyau Chen

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

View Study Details

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Lead Researcher: Yuhchyau Chen

There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.

View Study Details

Genotoxicity Assessment for Patients Receiving Large Field Irradiation

Lead Researcher: Yuhchyau Chen

The purpose of the research study is to evaluate an automated, laser-based technique for measuring DNA damage caused by radiation during cancer treatment in immature red blood cells.

View Study Details

Publications

Journal Articles

10/2021
Zhu R, Yang X, Xue X, Shen M, Chen F, Chen X, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y. "Retraction notice to "Neuroendocrine differentiation contributes to radioresistance development and metastatic potential increase in non-small cell lung cancer" [Biochim. Biophys. Acta, Mol. Cell Res. Volume 1865, Issue 12, December 2018, Pages 1878-1890]." Biochimica et biophysica acta. Molecular cell research.. 2021 Oct 0; 1868(11):119097. Epub 2021 Aug 07.

8/2021
Shen M, Tsai Y, Zhu R, Keng PC, Chen Y, Chen Y, Lee SO. "Retraction notice to "FASN-TGF-?1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells" [BBA - Molecular and Cell Biology of Lipids 1863/3 (March 2018) 313-322]." . 2021 Aug 0; 1866(8):158946. Epub 2021 Apr 28.

2021
Bitterman DS; Winter KA; Hong TS; Fuchs CS; Regine WF; Abrams RA; Safran H; Hoffman JP; Benson AB; Kasunic T; Mulcahy M; Strauss JF; DiPetrillo T; Stella PJ; Chen Y; Plastaras JP; Crane CH. "Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704" . Int J Radiat Oncol Biol Phys. 2021; 109(1): 201-211.

Books & Chapters

2014
Chapter Title: Upper Respiratory and Digestive System: Pharynx, Larynx, and Xerostomia
Book Title: ALERT-Adverse Late Effects of Cancer Treatment
Author List: Mittal B; Chen Y; Eisbruch A
Edited By: Rubin P; Constine LS; Marks LB
Published By: Springer-Verlag 2014 in Berlin Heidelberg

2011
Chapter Title: Translational Research in Lung Cancer
Book Title: Advances in Radiation Oncology in Lung Cancer
Author List: Singh D; Bylund K; Chen Y
Edited By: Jeremic B
Published By: Springer-Verlag GmbH 2011 in Heidelberg

2007
Chapter Title: Advances in Chemoradiation Treatment of Locoregionally Advanced Non-small Cell Lung Cancer
Book Title: Lung Cancer: Translational & Emerging Therapies
Author List: Milano MT, Chen Y
Edited By: Pandya K, Brahmer JU, Hidalgo M
Published By: Taylor and Francis 2007 in New York, NY

VIEW ALL PUBLICATIONS